Delcath Expands Phase III Trial For Metastatic Melanoma To Include St. Luke’s Cancer Center

Delcath Systems, Inc. (Nasdaq: DCTH) announced that the St. Luke’s Cancer Center of Bethlehem, PA, part of St. Luke’s Hospital & Health Network (St. Luke’s), has joined Delcath’s Phase III clinical trial for the treatment of inoperable metastatic melanoma in the liver using the Company’s Percutaneous Hepatic Perfusion (PHP) System for the isolated, high dose delivery of the anti-cancer agent melphalan.

More: continued here

Filed under: Dermatology on June 10th, 2008